This systematic review supports the use of a combination of a dopamine agonist with an aromatase inhibitor for a subgroup of male patients with prolactinoma, as the addition of anastrozole or letrozole improved the control of prolactin levels and may lead to shrinkage in tumor sizes. This evidence concerns the gene CYP19A1 and neoplasm.